JPWO2019180265A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019180265A5 JPWO2019180265A5 JP2021500355A JP2021500355A JPWO2019180265A5 JP WO2019180265 A5 JPWO2019180265 A5 JP WO2019180265A5 JP 2021500355 A JP2021500355 A JP 2021500355A JP 2021500355 A JP2021500355 A JP 2021500355A JP WO2019180265 A5 JPWO2019180265 A5 JP WO2019180265A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- inhibitor
- alkyl
- immune checkpoint
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 17
- 239000003112 inhibitor Substances 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 8
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 7
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims 7
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 5
- 108060004270 LAG3 Proteins 0.000 claims 4
- 102100017213 LAG3 Human genes 0.000 claims 4
- 102100019764 PDCD1 Human genes 0.000 claims 4
- 108060007796 SPATA2 Proteins 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000005842 heteroatoms Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102100009333 BTLA Human genes 0.000 claims 3
- 101700047069 BTLA Proteins 0.000 claims 3
- 101710012053 CD274 Proteins 0.000 claims 3
- 102100007290 CD274 Human genes 0.000 claims 3
- 101700015421 CD276 Proteins 0.000 claims 3
- 101710004393 HAVCR2 Proteins 0.000 claims 3
- 102100016384 HAVCR2 Human genes 0.000 claims 3
- 101710011976 PDCD1LG2 Proteins 0.000 claims 3
- 102100007289 PDCD1LG2 Human genes 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000000546 pharmaceutic aid Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 101710039842 ADORA2A Proteins 0.000 claims 2
- 229950002916 Avelumab Drugs 0.000 claims 2
- 102100003477 CMTM6 Human genes 0.000 claims 2
- 101710002888 CMTM6 Proteins 0.000 claims 2
- 102100005310 CTLA4 Human genes 0.000 claims 2
- 101700054183 CTLA4 Proteins 0.000 claims 2
- 229950009791 Durvalumab Drugs 0.000 claims 2
- 108010089187 Ipilimumab Proteins 0.000 claims 2
- 108010019706 Nivolumab Proteins 0.000 claims 2
- 208000001756 Virus Disease Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 108010072668 atezolizumab Proteins 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 108010010826 avelumab Proteins 0.000 claims 2
- 108010016436 durvalumab Proteins 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 108010026276 pembrolizumab Proteins 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims 1
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 1
- 229940121652 CTLA-4 inhibitors Drugs 0.000 claims 1
- 101710007023 ESAG4 Proteins 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 229940121655 PD-1 inhibitors Drugs 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 229940121656 PD-L1 inhibitors Drugs 0.000 claims 1
- 239000012272 PD-L2 inhibitor Substances 0.000 claims 1
- 229940121654 PD-L2 inhibitors Drugs 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 claims 1
- 229950007217 Tremelimumab Drugs 0.000 claims 1
- 125000005418 aryl aryl group Chemical group 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 125000004432 carbon atoms Chemical group C* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000006165 cyclic alkyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 230000003308 immunostimulating Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 101700032180 psaA Proteins 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 108010072993 tremelimumab Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18163705 | 2018-03-23 | ||
| EP18163705.9 | 2018-03-23 | ||
| EP18163703 | 2018-03-23 | ||
| EP18163703.4 | 2018-03-23 | ||
| PCT/EP2019/057364 WO2019180265A1 (en) | 2018-03-23 | 2019-03-25 | Combinations of macrolide compounds and immune checkpoint inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523930A JP2021523930A (ja) | 2021-09-09 |
| JPWO2019180265A5 true JPWO2019180265A5 (ko) | 2022-03-30 |
Family
ID=66041436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500355A Pending JP2021523930A (ja) | 2018-03-23 | 2019-03-25 | マクロライド化合物と免疫チェックポイント阻害剤との組み合わせ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210040134A1 (ko) |
| EP (1) | EP3768277A1 (ko) |
| JP (1) | JP2021523930A (ko) |
| KR (1) | KR20200134251A (ko) |
| CN (1) | CN112188893A (ko) |
| AU (1) | AU2019237257A1 (ko) |
| CA (1) | CA3094747A1 (ko) |
| WO (1) | WO2019180265A1 (ko) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3127315A (en) | 1964-03-31 | Hypocholesterolemic agent m- | ||
| EP0254534A3 (en) * | 1986-07-24 | 1991-04-17 | William S. Robinson | Erythromycin derivatives and compositions and use for inhibiting virus replication and disease |
| AU731301B2 (en) | 1996-07-05 | 2001-03-29 | Biotica Technology Limited | Erythromycins and process for their preparation |
| GB9814006D0 (en) | 1998-06-29 | 1998-08-26 | Biotica Tech Ltd | Polyketides and their synthesis |
| AU4858801A (en) | 2000-04-13 | 2001-10-30 | Biotica Tech Ltd | Hybrid glycosylated products and their production and use |
| JP2003327536A (ja) | 2002-03-07 | 2003-11-19 | Kitasato Inst:The | ヒト免疫不全症候群ウイルスの感染、増殖抑制剤 |
| GB0327720D0 (en) * | 2003-11-28 | 2003-12-31 | Biotica Tech Ltd | Erythromycins and process for their preparation |
| GB0327721D0 (en) * | 2003-11-28 | 2003-12-31 | Biotica Tech Ltd | Polyketides and their synthesis |
| US7767797B1 (en) * | 2004-09-30 | 2010-08-03 | Synovo Gmbh | Macrocyclic compounds and methods of use thereof |
| US20090077490A1 (en) | 2005-06-30 | 2009-03-19 | Takehiko Hanada | Monitor server apparatus |
| AU2014339816B2 (en) * | 2013-10-25 | 2020-05-28 | Pharmacyclics Llc | Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| JP2018521058A (ja) * | 2015-06-29 | 2018-08-02 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法 |
| JP7100653B2 (ja) * | 2017-02-22 | 2022-07-13 | アイエスアール イミューン システム レギュレイション ホールディング アクチエボラグ（パブル） | 新規な免疫刺激マクロライド |
| EP3585793B1 (en) * | 2017-02-22 | 2021-01-06 | ISR Immune System Regulation Holding AB (publ) | Novel immune stimulating macrolide |
-
2019
- 2019-03-25 JP JP2021500355A patent/JP2021523930A/ja active Pending
- 2019-03-25 US US17/040,680 patent/US20210040134A1/en not_active Abandoned
- 2019-03-25 WO PCT/EP2019/057364 patent/WO2019180265A1/en active Application Filing
- 2019-03-25 CN CN201980034615.7A patent/CN112188893A/zh active Pending
- 2019-03-25 AU AU2019237257A patent/AU2019237257A1/en active Pending
- 2019-03-25 EP EP19715414.9A patent/EP3768277A1/en active Pending
- 2019-03-25 KR KR1020207029157A patent/KR20200134251A/ko unknown
- 2019-03-25 CA CA3094747A patent/CA3094747A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matsuki et al. | Checkpoint inhibitors and other immune therapies for Hodgkin and non-Hodgkin lymphoma | |
| Pan et al. | Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1–CH3 fusion protein | |
| JP2019511212A5 (ko) | ||
| CA3047394A1 (en) | Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment | |
| CN110812478B (zh) | 免疫疗法与mdm2抑制剂的组合 | |
| RU2019138067A (ru) | Биспецифическое антитело против ox40 и ctla-4 | |
| JP2020511512A5 (ko) | ||
| KR20180004740A (ko) | 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제 | |
| JP2019503349A5 (ko) | ||
| JP2018531215A6 (ja) | 血液由来のがんの治療における使用を目的とする免疫チェックポイント阻害物質 | |
| JP2019529418A (ja) | 抗体およびチェックポイント阻害剤の併用療法 | |
| JP2020502147A5 (ko) | ||
| JP2023165946A (ja) | Ｅｐ４阻害剤およびその使用 | |
| JP2019524791A5 (ko) | ||
| Masoumi et al. | The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle | |
| FI3630143T3 (fi) | Onkolyyttinen virus ja menetelmä | |
| CA3168368A1 (en) | Antibody-drug conjugate including novel cyclic dinucleotide derivative | |
| TW202337439A (zh) | 用於ｈｉｖ病毒感染之治療性化合物 | |
| JP2023548522A (ja) | 免疫チェックポイント阻害剤と抗体－アマトキシンコンジュゲートの組合せを含む癌治療に使用するための組成物 | |
| JPWO2019180265A5 (ko) | ||
| JP2022545504A (ja) | ウロリチンと免疫療法治療との組み合わせ | |
| JP2019526528A5 (ko) | ||
| RU2022102355A (ru) | Кристаллические формы 5-бром-2,6-ди(1h-пиразол-1-ил)пиримидин-4- амина и новых солей | |
| US20220008383A1 (en) | Compositions and methods of enhancing immunotherapies | |
| EP3733708A1 (en) | Immune checkpoint molecule inhibitor |